Xavier Bosch

Xavier Bosch

Xavier Bosch
Cargo

Emeritus researcher at the Catalan Institute of Oncology (ICO), senior researcher at the Bellvitge Biomedical Research Institute (IDIBELL) and lecturer in the Faculty of Health Sciences at the Universitat Oberta de Catalunya (UOC)

Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Open University of Catalonia (UOC)
Topics
vaccines, cancer, HPV

High-risk Human Papillomavirus (HPV) genotypes linked to reduced male fertility

Sperm
HPV
High-risk Human Papillomavirus (HPV) genotypes linked to reduced male fertility
SMC Spain

The sperm of men infected with high-risk genotypes of the human papillomavirus (HPV) suffers more damage from oxidative stress and has a weaker immune response, which can lead to reduced fertility. This is one of the conclusions of a study published in the journal Frontiers in Cellular and Infection Microbiology. The research compared the semen of 20 adults infected with high-risk genotypes, seven infected with low-risk genotypes, and 43 adults without infections.

0

Reaction to study examining effectiveness of papillomavirus vaccine in the United States

vaccine
vaccines
Reaction to study examining effectiveness of papillomavirus vaccine in the United States
SMC Spain

In the United States, the human papillomavirus vaccine began to be recommended in 2006 for girls aged 9-26 years. A study published in the journal JAMA Health Forum concludes that the campaign significantly reduced the risk of HPV infection in vaccinated women. In addition, herd immunity reduced the likelihood of infection in unvaccinated women.

Subscribe to RSS - Xavier Bosch